The Value of Insulin-like Growth Factor in Urinary Exosomes of Bladder Urothelial Carcinoma
-
摘要:
目的 探讨尿液外泌体中胰岛素样生长因子2(insulin-like growth factor-2, IGF2)在膀胱尿路上皮癌诊断中的价值。 方法 选取北京协和医院2020年9月至12月诊治的膀胱尿路上皮癌患者作为试验组,同期非尿路上皮癌患者为对照组。采用荧光RT-PCR法检测样本尿液外泌体中IGF2表达水平。以膀胱镜检查或经尿道膀胱肿瘤切除术病理检查结果为金标准,计算尿液外泌体中IGF2表达水平以及诊断膀胱尿路上皮癌的灵敏度、特异度、阳性似然比和阴性似然比。 结果 共纳入尿路上皮癌患者35例,平均年龄(65.43±12.22)岁;非尿路上皮癌患者60例,平均年龄(51.68±13.07)岁。尿液外泌体中IGF2诊断膀胱尿路上皮癌的灵敏度为71.4%(95% CI:53.5%~84.8%),特异度为90%(95% CI:78.8%~95.9%),阳性似然比为7.14(95% CI:3.25~15.7),阴性似然比为0.32(95% CI:0.19~0.54)。 结论 尿液外泌体中IGF2有望作为膀胱尿路上皮癌的初筛指标。
Abstract:Objective To investigate the diagnostic value of insulin-like growth factor 2 (IGF2) in urine exosomes for bladder urothelial carcinoma. Methods The patients with bladder urothelial cancer admitted in Peking Union Medical College Hospital from September to December 2020 were selected as the research objects, and the patients with non-malignant urinary system disease cancers admitted in the same period were selected as the control group. Fluorescent RT-PCR was used to detect the level of IGF2 in urine exosomes. The pathological results of cystoscopy or transurethral bladder tumor resection were regards as the gold standard, and the sensitivity, specificity, positive likelihood ratio and negative likelihood ratio of the diagnosis of bladder cancer were calculated based on the expression level of IGF2 in urine exosomes. Results There were 35 cases in the urothelial cancer group, with an average age of (65.43±12.22) years, and there were 60 cases in the non-urothelial cancer group, with an average age of (51.68±13.07) years. The sensitivity of urinary exosomes IGF2 in diagnosing bladder urothelial carcinoma is 71.4% (95% CI: 53.5%-84.8%), specificity is 90% (95% CI: 78.8%-95.9%), and the positive likelihood ratio is 7.14 (95%CI: 3.25-15.7), the negative likelihood ratio was 0.32 (95%CI: 0.19-0.54). Conclusions The content of IGF2 in urine exosomes is promising as a preliminary screening index for bladder cancer.
-
Key words:
- bladder urothelial carcinoma /
- exosomes /
- insulin-like growth factor 2
-
[1] Livingstone C. IGF2 and cancer [J]. Endocr Relat Cancer, 2013, 20: R321-339. [2] Vennin C, Spruyt N, Robin Y M, et al. The long non-coding RNA 91H increases aggressive phenotype of breast cancer cells and up-regulates H19/IGF2 expression through epigenetic modifications [J]. Cancer Lett, 2017, 385: 198-206. [3] Dong Y, Li J, Han F, et al. High IGF2 expression is associated with poor clinical outcome in human ovarian cancer [J]. Oncol Rep, 2015, 34: 936-942. [4] Weischenfeldt J, Dubash T, Drainas A P, et al. Pan-cancer analysis of somatic copy-number alterations implicates IRS4 and IGF2 in enhancer hijacking [J]. Nat Genet, 2017, 49: 65-74. [5] Vidal S J, Rodriguez-bravo V, Quinn S A, et al. A targetable GATA2-IGF2 axis confers aggressiveness in lethal prostate cancer [J]. Cancer Cell, 2015, 27: 223-239. [6] Pegtel D M, Gould S J. Exosomes [J]. Annu Rev Biochem, 2019, 88: 487-514. [7] Richters A, Aben K K H, Kiemeney L. The global burden of urinary bladder cancer: an update [J]. World J Urol, 2020, 38: 1895-1904. [8] Cambier S, Sylvester R J, Collette L, et al. EORTC Nomograms and Risk Groups for Predicting Recurrence, Progression, and Disease-specific and Overall Survival in Non-Muscle-invasive Stage Ta-T1 Urothelial Bladder Cancer Patients Treated with 1-3 Years of Maintenance Bacillus Calmette-Guérin [J]. Eur Urol, 2016, 69: 60-69. [9] Yafi F A, Brimo F, Auger M, et al. Is the performance of urinary cytology as high as reported historically? A contemporary analysis in the detection and surveillance of bladder cancer [J]. Urol Oncol, 2014, 32: 27.e1-6. [10] 李腾林, 张焕涛, 陆身修,等. 尿肿瘤标志物联合检测在膀胱癌早期诊断中的应用价值[J].中外医学研究,2021,19:80-82.. [11] Bravaccini S. Fluorescence In Situ Hybridization in Urine Samples (UroVysion Kit) [J]. Methods Mol Biol, 2021, 2292: 35-48. [12] Zhou L, Yang K, Li X, et al. Application of fluorescence in situ hybridization in the detection of bladder transitional-cell carcinoma: A multi-center clinical study based on Chinese population [J]. Asian J Urol, 2019, 6: 114-121. [13] Ribal M J, Mengual L, Lozano J J, et al. Gene expression test for the non-invasive diagnosis of bladder cancer: A prospective, blinded, international and multicenter validation study [J]. Eur J Cancer, 2016, 54: 131-138. [14] Bobrie A, Colombo M, Krumeich S, et al. Diverse subpopulations of vesicles secreted by different intracellular mechanisms are present in exosome preparations obtained by differential ultracentrifugation [J]. J Extracell Vesicles, 2012, 1 [15] Zhang L, Yu D. Exosomes in cancer development, metastasis, and immunity [J]. Biochim Biophys Acta Rev Cancer, 2019, 1871: 455-468. -

计量
- 文章访问数: 72
- HTML全文浏览量: 18
- PDF下载量: 19
- 被引次数: 0